Loading...
Market
What will be Pfizer's stock price change following the withdrawal of Oxbryta by December 31, 2024?
3
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock price data from financial markets
Story
Pfizer ($PFE) Withdraws Sickle Cell Drug Oxbryta from Global Markets
Sep 25, 2024, 09:07 PM
Pfizer Inc. ($PFE) announced on Wednesday that it is voluntarily withdrawing all lots of its sickle cell disease treatment Oxbryta (voxelotor) from worldwide markets. The decision comes after data indicated an imbalance in vaso-occlusive crises and fatal events associated with the drug. This withdrawal marks a significant setback for Pfizer, following its $5.4 billion acquisition of Global Blood Therapeutics, the original developer of Oxbryta. The company stated that the overall benefit of Oxbryta no longer outweighs the risks involved.
View original story
Similar markets
Yes • 50%
No • 50%
Decrease by more than 5% • 25%
Decrease by 1-5% • 25%
No significant change • 25%
Increase • 25%
Introduce a new sickle cell treatment • 25%
Acquire another company with a sickle cell treatment • 25%
Exit the sickle cell treatment market • 25%
No major action • 25%
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Market cap increases by over 10% • 25%
Market cap increases by 0-10% • 25%
Market cap decreases by 0-10% • 25%
Market cap decreases by over 10% • 25%
Outperforms by more than 5% • 25%
Outperforms by 0% to 5% • 25%
Underperforms by 0% to 5% • 25%
Underperforms by more than 5% • 25%
